ESH AL 2024 | The current landscape of treatment for BPDCN
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the current landscape of treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). He mentions tagraxofusp, a CD123-targeted agent that is approved to treat BPDCN in Europe and the US, as well as pivekimab sunirine, an antibody-drug conjugate showing efficacy in relapsed BPDCN. Additionally, ongoing investigations explore the potential of combining venetoclax with other agents in BPDCN treatment. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Cimeio Therapeutics: Consultant; IDRx: Consultant; Jnana Therapeutics: Consultant; ProteinQure: Consultant; Qiagen: Consultant; Medzown: Stokeholder, SAB; AbbVie: Research Support; Stemline Therapeutics: Research Support.
